# ArriVent BioPharma, Inc.: financial statements, quarterly

AVBP · Nasdaq · CIK 1868279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avbp.md) · [Financials](/companies/avbp/financials.md) · [Filings](/companies/avbp/filings.md) · [Insiders](/companies/avbp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avbp/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [14.3](/filings/0001558370-24-015624.md) | [20.0 d](/filings/0001558370-25-001999.md) | [17.0](/filings/0001558370-25-007276.md) | [21.8](/filings/0001558370-25-010975.md) | [20.1](/filings/0001104659-25-108847.md) | [20.2 d](/filings/0001104659-26-024127.md) | [61.3](/filings/0001104659-26-058650.md) | [27.7](/filings/0001104659-26-094902.md) | [32.2](/filings/0001104659-25-108847.md) | [32.2 d](/filings/0001104659-26-024127.md) | [37.6](/filings/0001104659-26-058650.md) | [42.3](/filings/0001104659-26-094902.md) |
| Operating income | $m | [(16.7)](/filings/0001558370-24-015624.md) | [(23.1) d](/filings/0001558370-25-001999.md) | [(20.7)](/filings/0001558370-25-007276.md) | [(25.7)](/filings/0001558370-25-010975.md) | [(24.2)](/filings/0001104659-25-108847.md) | [(23.7) d](/filings/0001104659-26-024127.md) | [(66.8)](/filings/0001104659-26-058650.md) | [(33.6)](/filings/0001104659-26-094902.md) | [(38.3)](/filings/0001104659-25-108847.md) | [(38.8) d](/filings/0001104659-26-024127.md) | [(46.1)](/filings/0001104659-26-058650.md) | [(52.7)](/filings/0001104659-26-094902.md) |
| Net income | $m | [(14.4)](/filings/0001558370-24-015624.md) | [(21.2) d](/filings/0001558370-25-001999.md) | [(17.4)](/filings/0001104659-25-108847.md) | [(21.9)](/filings/0001104659-25-108847.md) | [(20.6)](/filings/0001104659-25-108847.md) | [(20.6) d](/filings/0001104659-26-024127.md) | [(64.4)](/filings/0001104659-26-094902.md) | [(31.4)](/filings/0001104659-26-094902.md) | [(35.0)](/filings/0001104659-25-108847.md) | [(35.5) d](/filings/0001104659-26-024127.md) | [(43.3)](/filings/0001104659-26-094902.md) | [(49.9)](/filings/0001104659-26-094902.md) |
| Diluted EPS | $ per share | [(5.52)](/filings/0001558370-24-015624.md) | not reported | [(0.70)](/filings/0001558370-25-007276.md) | [(0.65)](/filings/0001558370-25-010975.md) | [(0.61)](/filings/0001104659-25-108847.md) | not reported | [(1.90)](/filings/0001104659-26-058650.md) | [(0.90)](/filings/0001104659-26-094902.md) | [(0.83)](/filings/0001104659-25-108847.md) | not reported | [(0.96)](/filings/0001104659-26-058650.md) | [(1.05)](/filings/0001104659-26-094902.md) |
| Basic EPS | $ per share | [(5.52)](/filings/0001558370-24-015624.md) | not reported | [(0.70)](/filings/0001558370-25-007276.md) | [(0.65)](/filings/0001558370-25-010975.md) | [(0.61)](/filings/0001104659-25-108847.md) | not reported | [(1.90)](/filings/0001104659-26-058650.md) | [(0.90)](/filings/0001104659-26-094902.md) | [(0.83)](/filings/0001104659-25-108847.md) | not reported | [(0.96)](/filings/0001104659-26-058650.md) | [(1.05)](/filings/0001104659-26-094902.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [150](/filings/0001558370-25-001999.md) | [317](/filings/0001558370-24-007197.md) | [299](/filings/0001558370-24-012236.md) | [283](/filings/0001558370-24-015624.md) | [74.3](/filings/0001104659-26-024127.md) | [49.9](/filings/0001558370-25-007276.md) | [113](/filings/0001558370-25-010975.md) | [113](/filings/0001104659-25-108847.md) | [45.5](/filings/0001104659-26-094902.md) | [62.1](/filings/0001104659-26-058650.md) | [155](/filings/0001104659-26-094902.md) |
| Current assets | $m | not reported | [160](/filings/0001558370-25-001999.md) | [327](/filings/0001558370-24-007197.md) | [309](/filings/0001558370-24-012236.md) | [292](/filings/0001558370-24-015624.md) | [227](/filings/0001104659-26-024127.md) | [186](/filings/0001558370-25-007276.md) | [250](/filings/0001558370-25-010975.md) | [321](/filings/0001104659-25-108847.md) | [333](/filings/0001104659-26-094902.md) | [349](/filings/0001104659-26-058650.md) | [394](/filings/0001104659-26-094902.md) |
| Total assets | $m | not reported | [163](/filings/0001558370-25-001999.md) | [328](/filings/0001558370-24-007197.md) | [309](/filings/0001558370-24-012236.md) | [293](/filings/0001558370-24-015624.md) | [275](/filings/0001104659-26-024127.md) | [215](/filings/0001558370-25-007276.md) | [270](/filings/0001558370-25-010975.md) | [327](/filings/0001104659-25-108847.md) | [333](/filings/0001104659-26-094902.md) | [349](/filings/0001104659-26-058650.md) | [395](/filings/0001104659-26-094902.md) |
| Current liabilities | $m | not reported | [11.6](/filings/0001558370-25-001999.md) | [10.0](/filings/0001558370-24-007197.md) | [12.1](/filings/0001558370-24-012236.md) | [15.2](/filings/0001558370-24-015624.md) | [17.3](/filings/0001104659-26-024127.md) | [13.0](/filings/0001558370-25-007276.md) | [19.6](/filings/0001558370-25-010975.md) | [21.6](/filings/0001104659-25-108847.md) | [25.9](/filings/0001104659-26-094902.md) | [25.0](/filings/0001104659-26-058650.md) | [27.8](/filings/0001104659-26-094902.md) |
| Total liabilities | $m | not reported | [11.8](/filings/0001558370-25-001999.md) | [10.1](/filings/0001558370-24-007197.md) | [12.2](/filings/0001558370-24-012236.md) | [15.2](/filings/0001558370-24-015624.md) | [17.3](/filings/0001104659-26-024127.md) | [13.0](/filings/0001558370-25-007276.md) | [19.6](/filings/0001558370-25-010975.md) | [21.6](/filings/0001104659-25-108847.md) | [25.9](/filings/0001104659-26-094902.md) | [25.3](/filings/0001104659-26-058650.md) | [27.9](/filings/0001104659-26-094902.md) |
| Shareholders' equity | $m | [(133)](/filings/0001558370-24-015624.md) | [(153)](/filings/0001104659-26-024127.md) | [318](/filings/0001104659-25-108847.md) | [297](/filings/0001104659-25-108847.md) | [277](/filings/0001104659-25-108847.md) | [258](/filings/0001104659-26-094902.md) | [203](/filings/0001104659-26-094902.md) | [250](/filings/0001104659-26-094902.md) | [305](/filings/0001104659-25-108847.md) | [307](/filings/0001104659-26-094902.md) | [324](/filings/0001104659-26-094902.md) | [367](/filings/0001104659-26-094902.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.4) d](/filings/0001558370-24-015624.md) | [(14.9) d](/filings/0001558370-25-001999.md) | [(18.6)](/filings/0001558370-25-007276.md) | [(19.1) d](/filings/0001558370-25-010975.md) | [(16.3) d](/filings/0001104659-25-108847.md) | [(16.2) d](/filings/0001104659-26-024127.md) | [(68.0)](/filings/0001104659-26-058650.md) | [(26.1) d](/filings/0001104659-26-094902.md) | [(35.8) d](/filings/0001104659-25-108847.md) | [(30.7) d](/filings/0001104659-26-024127.md) | [(41.9)](/filings/0001104659-26-058650.md) | [(39.6) d](/filings/0001104659-26-094902.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.3](/filings/0001558370-24-007197.md) | [2.0](/filings/0001558370-24-012236.md) | [2.6](/filings/0001558370-24-015624.md) | [25.0](/filings/0001558370-25-007276.md) | [33.5](/filings/0001558370-25-010975.md) | [33.6](/filings/0001104659-25-108847.md) | [33.9](/filings/0001104659-26-058650.md) | [35.0](/filings/0001104659-26-094902.md) | [41.9](/filings/0001104659-25-108847.md) | [45.1](/filings/0001104659-26-058650.md) | [47.6](/filings/0001104659-26-094902.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,307,729 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094902.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.